Last updated: October 15, 2026
AZACTAM in plastic container is the injectable formulation of aztreonam, a monobactam antibiotic used primarily for serious gram-negative bacterial infections, including infections caused by organisms resistant to other beta-lactam antibiotics. Its commercial position is mature and largely genericized. The product has limited patent value, no meaningful regulatory exclusivity, and financial performance driven more by hospital procurement, supply reliability, product availability, and niche clinical demand than by brand pricing power.
Product-level revenue for AZACTAM in plastic container is not separately disclosed in public filings. The financial trajectory is therefore best assessed through the structure of the aztreonam market, FDA regulatory records, generic competition, hospital injectable purchasing, and the product’s lack of remaining exclusivity.
What is AZACTAM in plastic container?
AZACTAM in plastic container contains aztreonam for injection, a beta-lactam antibiotic that targets aerobic gram-negative bacteria. The product is administered intravenously or intramuscularly and is used in hospitals and other institutional-care settings.
The plastic-container presentation is a ready-to-use or reconstituted injectable format intended to reduce preparation requirements relative to conventional powder vials. Depending on the specific presentation, the container may contain aztreonam in a compatible intravenous solution or a pharmacy-prepared injectable format. Product strength, diluent, container system, and NDC vary by manufacturer and package configuration.
| Attribute |
Product profile |
| Brand |
AZACTAM |
| Active ingredient |
Aztreonam |
| Drug class |
Monobactam antibacterial |
| Primary setting |
Hospitals and institutional care |
| Administration |
Intravenous or intramuscular |
| Main target organisms |
Aerobic gram-negative bacteria |
| Commercial status |
Mature, genericized injectable market |
| Key purchasing channel |
Hospital, group purchasing organization, distributor |
| Principal commercial drivers |
Availability, contract pricing, supply continuity, clinical niche |
| Product-level revenue disclosure |
Not separately reported publicly |
FDA labeling identifies aztreonam as a treatment for serious infections caused by susceptible gram-negative organisms, including lower respiratory tract, urinary tract, intra-abdominal, gynecologic, skin and skin-structure, and bloodstream infections.[1]
How does the aztreonam market generate revenue?
Aztreonam revenue is concentrated in institutional channels rather than retail pharmacies. The product is typically purchased through hospital pharmacies, integrated delivery networks, group purchasing organizations, wholesalers, and government contracts.
The market has several demand characteristics:
-
Niche clinical use: Aztreonam is not a broad first-line antibiotic for all bacterial infections. It is particularly relevant when clinicians require gram-negative coverage in patients with selected beta-lactam allergy concerns or when susceptibility data support its use.
-
Low outpatient exposure: The injectable form is primarily administered in hospitals or supervised care settings. This reduces direct-to-consumer exposure and limits retail pharmacy growth.
-
Generic price pressure: The active ingredient and core formulation have been available for decades. Multiple suppliers can compete on contract price, creating persistent pressure on branded revenue.
-
Supply sensitivity: Hospital buyers value dependable supply because antibiotic shortages can force treatment substitutions, emergency purchases, and formulary changes. A supplier with reliable manufacturing can retain share even without patent protection.
-
Low promotional intensity: Prescriber demand is usually driven by hospital protocols, infectious-disease consultation, susceptibility results, and formulary placement rather than brand advertising.
When did AZACTAM lose exclusivity?
The core aztreonam composition-of-matter patent protection expired years ago. The original product therefore has no current composition patent barrier capable of preventing generic entry.
FDA records identify AZACTAM as an established prescription product rather than a newly protected small-molecule medicine. The main commercial protections that once supported branded pricing, including patent protection and any applicable approval exclusivity, are no longer material to the current market.[2]
| Exclusivity category |
Current commercial significance |
| Composition-of-matter patent |
Expired |
| Core formulation protection |
No material barrier to standard generic competition |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
Not the principal protection for the product |
| Pediatric exclusivity |
Not commercially relevant to the current product |
| Method-of-use patents |
Unlikely to block ordinary generic aztreonam sales |
| Manufacturing patents |
May protect specific processes but do not generally prevent finished-dose competition |
The absence of meaningful exclusivity shifts value away from intellectual property and toward manufacturing economics, regulatory compliance, hospital contracting, and supply performance.
What patents protect AZACTAM in plastic container?
The core product is not protected today by a commercially meaningful patent estate comparable to that of a recently launched branded drug. Historic aztreonam patents covered the active compound and related pharmaceutical technology, but those rights have expired or no longer provide a practical market barrier.
Potentially relevant intellectual-property categories include:
- Container and closure systems
- Premixed injectable stability
- Storage and sterilization processes
- Manufacturing methods
- Packaging configurations
- Specific concentration or diluent combinations
These rights may affect a particular plastic-container presentation, but they generally do not prevent competitors from marketing aztreonam in alternative vials, bags, or containers if those products satisfy FDA requirements.
Are formulation patents commercially important?
Formulation and container patents can have value when they protect a technically difficult presentation. For aztreonam, that value is limited by the availability of alternative injectable formats and the age of the underlying drug.
A container-related patent could protect:
- A ready-to-use solution
- A specific diluent
- A stability profile
- A low-temperature or room-temperature storage condition
- A container material that reduces degradation
- A terminal sterilization or aseptic-processing method
These rights would normally create product differentiation rather than broad market exclusivity. Hospital buyers can often substitute among presentations if dose, route, compatibility, and administration requirements remain clinically acceptable.
What is the FDA regulatory status of AZACTAM?
AZACTAM is an FDA-approved prescription antibacterial product. Its regulatory position is mature, and the principal regulatory question is no longer initial approval but continued commercial availability and manufacturing compliance.
The FDA-approved label sets out dosing, contraindications, warnings, adverse reactions, microbiology, and use limitations.[1] Because aztreonam is an antibacterial product, changes in labeling, susceptibility interpretation, manufacturing sites, or supply status can materially affect commercial performance.
Does AZACTAM have Orange Book protection?
The Orange Book is relevant to approved aztreonam drug products and any listed patents associated with those products. For a mature product such as AZACTAM in plastic container, the commercial importance of Orange Book listings is limited unless an unexpired patent covers a specific presentation or method of use.
Generic applicants may rely on an abbreviated new drug application pathway when they can demonstrate bioequivalence and satisfy applicable pharmaceutical-equivalence requirements. A generic applicant would generally assess listed patents through the relevant certification pathway, including Paragraph III or Paragraph IV certifications where applicable.[3]
Are there Paragraph IV challenges to AZACTAM?
Paragraph IV litigation is unlikely to be a major current market event for the original AZACTAM product because the core drug is long genericized and the principal patents have expired.
A Paragraph IV challenge could still arise if a company sought approval for a protected delivery system, container technology, or a formulation with an unexpired listed patent. That type of challenge would concern a specific patent and presentation, not the underlying commercial availability of aztreonam.
| Litigation issue |
Current assessment |
| Challenge to core aztreonam compound |
Low relevance because core protection has expired |
| Challenge to standard injectable formulation |
Limited relevance |
| Challenge to plastic-container technology |
Possible only if an unexpired listed patent exists |
| Generic approval risk |
Primarily regulatory and manufacturing, not patent-based |
| Likely litigation driver |
Product-specific formulation or process rights |
No active patent dispute is required for generic competitors to enter the broader aztreonam market.
How strong is the AZACTAM patent estate?
The patent estate is weak as a current commercial defense. Its primary historical value was tied to the original aztreonam molecule and early pharmaceutical development. Those rights no longer support premium pricing or prevent competing products.
Patent-strength assessment
| Factor |
Assessment |
| Core molecule protection |
Weak or expired |
| Formulation protection |
Potentially narrow |
| Container protection |
Potentially narrow and design-aroundable |
| Method-of-use protection |
Limited practical impact |
| Manufacturing protection |
Relevant to process economics, not broad market exclusion |
| Generic-entry resistance |
Low |
| Litigation leverage |
Low to moderate for narrow presentation claims |
| Overall estate strength |
Low |
A supplier could still possess trade secrets, validated manufacturing procedures, regulatory know-how, supplier relationships, and quality-control systems. Those assets may be commercially important even though they do not create patent exclusivity.
Which companies are challenging or competing with AZACTAM?
Competition comes primarily from generic aztreonam manufacturers and suppliers of alternative gram-negative antibiotics. The competitor set can change based on FDA approvals, discontinuations, shortages, and commercial decisions.
Generic competition typically includes:
- Manufacturers of aztreonam injection in powder-vial form
- Suppliers of premixed or flexible-container presentations
- Contract manufacturers supplying institutional distributors
- Other beta-lactam and non-beta-lactam antibiotics used as clinical substitutes
The most important competitive distinction is often not the branded name. It is whether a supplier can offer the required strength, route, container, shelf life, and reliable delivery under hospital contract terms.
What generic-entry risks exist for AZACTAM?
Generic-entry risk is already realized rather than prospective. The market has transitioned from branded exclusivity to mature generic competition.
The remaining commercial risks are:
Price erosion
Hospital buyers can use multiple approved suppliers to negotiate lower prices. Contracting groups may favor the lowest reliable bid, especially for standard strengths and high-volume presentations.
Formulation substitution
A competing vial or bag can displace a plastic-container presentation if the hospital can accommodate differences in reconstitution, storage, preparation time, and administration.
Supply-driven switching
A shortage, manufacturing interruption, or quality event can cause hospitals to replace a product rapidly. Once a competitor is incorporated into pharmacy workflows, the original supplier may not automatically regain volume.
Regulatory delays
Changes in manufacturing sites, container components, sterilization processes, or labeling can delay supply and create openings for competitors.
Clinical substitution
When aztreonam is unavailable or expensive, clinicians may use other agents based on allergy history, susceptibility testing, renal function, infection site, and local stewardship policy.
What affects the financial trajectory of AZACTAM?
The financial trajectory is likely flat to declining on a branded-product basis, with intermittent volume or price increases during supply disruptions. The product lacks the characteristics of a high-growth pharmaceutical asset.
Revenue drivers
- Hospital utilization of injectable aztreonam
- Penetration of beta-lactam allergy pathways
- Gram-negative resistance patterns
- Hospital contract wins
- Product availability during competitor shortages
- Price increases permitted by purchasing contracts
- New or improved container formats
Revenue constraints
- Mature generic competition
- Limited outpatient use
- Antibiotic stewardship programs
- Availability of alternative therapies
- Hospital budget controls
- Low brand differentiation
- Lack of patent exclusivity
Because AZACTAM revenue is not separately disclosed by public companies, no verified product-level annual sales series can be stated. Parent-company filings generally aggregate mature pharmaceutical products into broader business segments, and distributor data are not equivalent to manufacturer net sales.
How does AZACTAM compare with competing antibiotics?
| Market factor |
AZACTAM |
Broad-spectrum beta-lactams |
Newer resistant-pathogen agents |
| Main use |
Selected gram-negative infections |
Broad empiric and targeted treatment |
Resistant infections |
| Patent protection |
Generally expired |
Often mixed |
Frequently stronger |
| Price power |
Low |
Low to moderate |
Moderate to high |
| Hospital role |
Niche |
Core formulary category |
Restricted or specialist use |
| Generic competition |
High |
High in mature products |
Variable |
| Growth outlook |
Stable to declining |
Volume-dependent |
May grow with resistance |
| Key differentiation |
Monobactam structure and clinical niche |
Spectrum and established protocols |
Resistance coverage and outcomes |
AZACTAM’s competitive value is concentrated in specific patients and hospital protocols rather than broad market growth.
What manufacturing and IP barriers remain?
Manufacturing is the principal practical barrier. Sterile injectable products require validated aseptic processing, container-closure integrity, particulate control, stability data, microbiological controls, and reliable active-ingredient supply.
A competitor must also establish:
- FDA-compliant manufacturing capacity
- Bioequivalence or pharmaceutical-equivalence support
- Container compatibility
- Sterility assurance
- Adequate shelf life
- Distribution and cold-chain or controlled-storage capability where required
- Hospital purchasing access
- Pharmacovigilance and complaint-handling systems
These barriers can reduce the number of dependable suppliers even when patent barriers are absent. A mature injectable market can therefore experience supply tightness without supporting durable branded pricing.
What is the outlook for AZACTAM?
The base-case outlook is mature and operationally driven:
- Revenue: Flat to declining over the long term unless shortages or price actions create temporary increases.
- Volume: Stable in hospitals with continued clinical demand for aztreonam, but vulnerable to therapeutic substitution.
- Price: Under pressure from generic contracting and purchasing-group negotiations.
- Patent value: Minimal.
- Regulatory value: Concentrated in approval maintenance and manufacturing compliance.
- Strategic value: Higher for supply reliability than for intellectual-property protection.
- M&A or licensing value: Limited for the legacy product alone; greater if bundled with sterile manufacturing capacity or a broader hospital-antibiotic portfolio.
A license involving AZACTAM in plastic container would likely be evaluated on manufacturing access, geographic rights, hospital contracts, supply continuity, and margin structure rather than patent duration.
Key Takeaways
- AZACTAM in plastic container is a mature aztreonam injectable product with no meaningful remaining core-molecule exclusivity.
- Its market is primarily institutional, with hospitals and group purchasing organizations controlling access and pricing.
- Product-level revenue is not separately disclosed in public filings.
- Generic-entry risk is already embedded in the market.
- The patent estate has limited current strength; container and formulation rights, if any, would likely be narrow.
- Manufacturing reliability, sterile capacity, hospital contracting, and supply continuity are more important than patent protection.
- Long-term revenue is likely stable to declining, with temporary upside during competitor shortages or supply disruptions.
- Biosimilar risk is not applicable because aztreonam is a chemically synthesized small molecule, not a biologic.
- A commercial transaction involving the product would depend more on operational execution and distribution than on exclusivity.
FAQs
Is AZACTAM in plastic container a biologic drug?
No. AZACTAM contains aztreonam, a chemically synthesized small-molecule antibiotic. Biosimilar regulation does not apply.
Can a generic company launch aztreonam without a license from the AZACTAM brand owner?
Yes, subject to FDA approval, applicable patent certifications, manufacturing compliance, and product requirements. A license from the brand owner is not generally required for an unpatented generic product.
Does AZACTAM have meaningful orphan-drug protection?
No current orphan-drug exclusivity is a central commercial barrier for the established aztreonam injectable product.
Why can a mature antibiotic remain commercially relevant after patent expiry?
Clinical niche, hospital protocols, susceptibility patterns, supply reliability, and limited therapeutic alternatives can preserve demand after patent expiry.
Is the plastic container itself likely to support premium pricing?
Only to a limited extent. A plastic container may reduce preparation burden or improve workflow, but hospitals can resist premiums when equivalent vial or bag presentations are available.
References
- U.S. Food and Drug Administration. (n.d.). AZACTAM (aztreonam) injection, prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (n.d.). ANDA submissions: Generic drug applications and patent certifications.
